Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression()()

Our group has previously reported that the majority of human melanomas (> 60%) express the metabotropic glutamate receptor 1 (GRM1) and that the glutamate release inhibitor riluzole, a drug currently used to treat amyotrophic lateral sclerosis, can induce apoptosis in GRM1-expressing melanoma cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenberg, Stephen A., Niglio, Scot A., Salehomoum, Negar, Chan, Joseph L.-K., Jeong, Byeong-Seon, Wen, Yu, Li, Jiadong, Fukui, Jami, Chen, Suzie, Shin, Seung-Shick, Goydos, James S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350641/
https://www.ncbi.nlm.nih.gov/pubmed/25749171
http://dx.doi.org/10.1016/j.tranon.2014.11.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350641/
https://www.ncbi.nlm.nih.gov/pubmed/25749171
http://dx.doi.org/10.1016/j.tranon.2014.11.001

Ejemplares similares